Next Article in Journal
New Insights into the Pathophysiology and Treatment of Fibromyalgia
Next Article in Special Issue
NF-κB Members Left Home: NF-κB-Independent Roles in Cancer
Previous Article in Journal
Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology
Article Menu

Export Article

Open AccessFeature PaperReview
Biomedicines 2017, 5(2), 21; doi:10.3390/biomedicines5020021

Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB

Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dundee DD15EH, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Veronique Baud
Received: 31 March 2017 / Revised: 2 May 2017 / Accepted: 4 May 2017 / Published: 9 May 2017
(This article belongs to the Special Issue Roles of NF-kB in Cancer and Their Therapeutic Approaches)
View Full-Text   |   Download PDF [2473 KB, uploaded 9 May 2017]   |  

Abstract

Cancer is often characterised by the presence of hypoxia and inflammation. Paramount to the mechanisms controlling cellular responses under such stress stimuli, are the transcription factor families of Hypoxia Inducible Factor (HIF) and Nuclear Factor of κ-light-chain-enhancer of activated B cells (NF-κB). Although, a detailed understating of how these transcription factors respond to their cognate stimulus is well established, it is now appreciated that HIF and NF-κB undergo extensive crosstalk, in particular in pathological situations such as cancer. Here, we focus on the current knowledge on how HIF is activated by inflammation and how NF-κB is modulated by hypoxia. We summarise the evidence for the possible mechanism behind this activation and how HIF and NF-κB function impacts cancer, focusing on colorectal, breast and lung cancer. We discuss possible new points of therapeutic intervention aiming to harness the current understanding of the HIF-NF-κB crosstalk. View Full-Text
Keywords: NF-κB; hypoxia; inflammation; κB Kinase (IKK); Prolyl Hydroxylases (PHDs); cancer; Transforming Growth Factor-β-Activated Kinase 1 (TAK1); Factor Inhibiting HIF (FIH) NF-κB; hypoxia; inflammation; κB Kinase (IKK); Prolyl Hydroxylases (PHDs); cancer; Transforming Growth Factor-β-Activated Kinase 1 (TAK1); Factor Inhibiting HIF (FIH)
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

D’Ignazio, L.; Batie, M.; Rocha, S. Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. Biomedicines 2017, 5, 21.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top